These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 27233447)

  • 1. A cellular high-throughput screening approach for therapeutic trans-cleaving ribozymes and RNAi against arbitrary mRNA disease targets.
    Yau EH; Butler MC; Sullivan JM
    Exp Eye Res; 2016 Oct; 151():236-55. PubMed ID: 27233447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of lead hammerhead ribozyme candidates against human rod opsin mRNA for retinal degeneration therapy.
    Abdelmaksoud HE; Yau EH; Zuker M; Sullivan JM
    Exp Eye Res; 2009 May; 88(5):859-79. PubMed ID: 19094986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid, cell-based toxicity screen of potentially therapeutic post-transcriptional gene silencing agents.
    Kolniak TA; Sullivan JM
    Exp Eye Res; 2011 May; 92(5):328-37. PubMed ID: 21256844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic Screening, Rational Development, and Initial Optimization of Efficacious RNA Silencing Agents for Human Rod Opsin Therapeutics.
    Yau EH; Taggart RT; Zuber M; Trujillo AJ; Fayazi ZS; Butler MC; Sheflin LG; Breen JB; Yu D; Sullivan JM
    Transl Vis Sci Technol; 2019 Nov; 8(6):28. PubMed ID: 31853424
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Discovery with Potential to Revitalize Hammerhead Ribozyme Therapeutics for Treatment of Inherited Retinal Degenerations.
    Trujillo AJ; Myers JM; Fayazi ZS; Butler MC; Sullivan JM
    Adv Exp Med Biol; 2019; 1185():119-124. PubMed ID: 31884599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hammerhead ribozymes designed to cleave all human rod opsin mRNAs which cause autosomal dominant retinitis pigmentosa.
    Sullivan JM; Pietras KM; Shin BJ; Misasi JN
    Mol Vis; 2002 Apr; 8():102-13. PubMed ID: 11961505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Pathogenic Variations in the Human Rhodopsin Gene (hRHO) on the Predicted Accessibility for a Lead Candidate Ribozyme.
    Froebel BR; Trujillo AJ; Sullivan JM
    Invest Ophthalmol Vis Sci; 2017 Jul; 58(9):3576-3591. PubMed ID: 28715844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ribozyme knockdown of the gamma-subunit of rod cGMP phosphodiesterase alters the ERG and retinal morphology in wild-type mice.
    Liu J; Timmers AM; Lewin AS; Hauswirth WW
    Invest Ophthalmol Vis Sci; 2005 Oct; 46(10):3836-44. PubMed ID: 16186371
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ribozyme-targeted destruction of RNA associated with autosomal-dominant retinitis pigmentosa.
    Drenser KA; Timmers AM; Hauswirth WW; Lewin AS
    Invest Ophthalmol Vis Sci; 1998 Apr; 39(5):681-9. PubMed ID: 9538873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variables and strategies in development of therapeutic post-transcriptional gene silencing agents.
    Sullivan JM; Yau EH; Kolniak TA; Sheflin LG; Taggart RT; Abdelmaksoud HE
    J Ophthalmol; 2011; 2011():531380. PubMed ID: 21785698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutation-independent rhodopsin gene therapy by knockdown and replacement with a single AAV vector.
    Cideciyan AV; Sudharsan R; Dufour VL; Massengill MT; Iwabe S; Swider M; Lisi B; Sumaroka A; Marinho LF; Appelbaum T; Rossmiller B; Hauswirth WW; Jacobson SG; Lewin AS; Aguirre GD; Beltran WA
    Proc Natl Acad Sci U S A; 2018 Sep; 115(36):E8547-E8556. PubMed ID: 30127005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bottlenecks in development of retinal therapeutic post-transcriptional gene silencing agents.
    Sullivan JM; Yau EH; Taggart RT; Butler MC; Kolniak TA
    Vision Res; 2008 Feb; 48(3):453-69. PubMed ID: 17976683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An allele-specific hammerhead ribozyme gene therapy for a porcine model of autosomal dominant retinitis pigmentosa.
    Shaw LC; Skold A; Wong F; Petters R; Hauswirth WW; Lewin AS
    Mol Vis; 2001 Jan; 7():6-13. PubMed ID: 11172137
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and validation of therapeutic hammerhead ribozymes for autosomal dominant diseases.
    Fritz JJ; Gorbatyuk M; Lewin AS; Hauswirth WW
    Methods Mol Biol; 2004; 252():221-36. PubMed ID: 15017052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A method for prediction of accessible sites on an mRNA sequence for target selection of hammerhead ribozymes.
    Mercatanti A; Rainaldi G; Mariani L; Marangoni R; Citti L
    J Comput Biol; 2002; 9(4):641-53. PubMed ID: 12323098
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Knockdown of wild-type mouse rhodopsin using an AAV vectored ribozyme as part of an RNA replacement approach.
    Gorbatyuk MS; Pang JJ; Thomas J; Hauswirth WW; Lewin AS
    Mol Vis; 2005 Aug; 11():648-56. PubMed ID: 16145542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ribozyme uses in retinal gene therapy.
    Hauswirth WW; Lewin AS
    Prog Retin Eye Res; 2000 Nov; 19(6):689-710. PubMed ID: 11029552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ribozyme gene therapy for autosomal dominant retinal disease.
    Hauswirth WW; LaVail MM; Flannery JG; Lewin AS
    Clin Chem Lab Med; 2000 Feb; 38(2):147-53. PubMed ID: 10834402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of antisense and ribozyme accessible sites on native mRNAs: application to NCOA3 mRNA.
    Scherr M; LeBon J; Castanotto D; Cunliffe HE; Meltzer PS; Ganser A; Riggs AD; Rossi JJ
    Mol Ther; 2001 Nov; 4(5):454-60. PubMed ID: 11708882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Attenuation of telomerase activity by hammerhead ribozymes targeting human telomerase RNA and telomerase reverse transcriptase in pancreatic carcinoma cells.
    Hayashidani Y; Hiyama E; Murakami Y; Sueda T
    Hiroshima J Med Sci; 2005 Mar; 54(1):21-7. PubMed ID: 15847061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.